Wedbush Says Buy Omeros (OMER) on Weakness from Mixed OMS103HP Phase 3 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Burrill Trims PT on Omeros (OMER) after OMS103HP Results, Keeps Buy Rating
December 28, 2012 8:55 AM ESTBurrill cut its price target on Omeros Corp. (NASDAQ: OMER) from $19 to $16 after OMS103HP did not meet its primary endpoint in patients undergoing arthroscopic partial meniscectomy surgery. However, the firm maintained a Market Outperform as OMS103HP achieved statistically significant reduction of postoperative pain (p=0.0003)... More
Needham & Company Reiterates Buy on Omeros Corp. (OMER) on Mixed OMS103HP Results
December 28, 2012 8:39 AM ESTNeedham & Company reiterated their Buy rating and $10 price target on Omeros Corp. (NASDAQ: OMER) following mixed Phase 3 trial results for OMS103HP that missed the primary endpoint but showed a statistically significant impact on early postoperative pain, a secondary endpoint. A second Phase 3 trial in... More
Omeros (OMER) Said Symptoms Subscale of the KOOS for OMS103HP Did Not Reach Statistical Significance
December 27, 2012 4:04 PM ESTOmeros Corporation (NASDAQ: OMER) reported results from its first pivotal Phase 3 clinical trial evaluating OMS103HP in patients undergoing arthroscopic partial meniscectomy surgery. In this multicenter, double-blind, Phase 3 clinical trial comparing OMS103HP to vehicle control in 344 subjects, the pre-specified primary endpoint was the Symptoms Subscale of the Knee Injury and Osteoarthritis Outcome Score (KOOS) a patient-reported measure that is comprised of questions about knee swelling, clicking, catching and stiffness. In addition, pain measured in the early postoperative period was a pre-specified secondary endpoint.
Although the Symptoms Subscale of the KOOS did not reach... More
